Last Updated : July 8, 2015
Details
FilesGeneric Name:
Siltuximab
Project Status:
Complete
Therapeutic Area:
Multicentric Castleman's disease (MCD)
Manufacturer:
Janssen Inc.
Brand Name:
Sylvant
Project Line:
Reimbursement Review
Project Number:
PC0052-000
Strength:
100mg/vial and 400mg/vial
Tumour Type:
Lymphoma
Indications:
Multicentric Castleman's Disease (MCD)
Funding Request:
For the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV)-negative and human herpes virus-8 (HHV-8)-negative
Review Status:
Complete
Sponsor:
Janssen Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : July 8, 2015